Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
CHD
MCID: CRN300
MIFTS: 62

Coronary Heart Disease 1 (CHD)

Categories: Blood diseases, Genetic diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Coronary Heart Disease 1

About this section

MalaCards integrated aliases for Coronary Heart Disease 1:

Name: Coronary Heart Disease 1 58 30
Coronary Heart Disease 58 77 30 56 6 17 74 64
Coronary Heart Disease, Susceptibility to, 1 58 74
Coronary Artery Disease 74 64
Heart, Coronary, Disease, Susceptibility to, Type 1 41
Coronary Heart Disease, Susceptibility to 58
Coronary Arteriosclerosis 74
Chds1 58
Chd 49

Classifications:

MalaCards categories:
Global: Genetic diseases
Anatomical: Blood diseases
See all MalaCards categories (disease lists)


Sources

Summaries for Coronary Heart Disease 1

About this section
PubMed Health : 64 About coronary artery disease: Coronary heart disease (CHD) is a disease in which a waxy substance called plaque (plak) builds up inside the coronary arteries. These arteries supply oxygen-rich blood to your heart muscle.When plaque builds up in the arteries, the condition is called atherosclerosis (ATH-er-o-skler-O-sis). The buildup of plaque occurs over many years.

MalaCards based summary : Coronary Heart Disease 1, also known as coronary heart disease, is related to diabetes mellitus, noninsulin-dependent and lung cancer, and has symptoms including tremor, angina pectoris and edema. An important gene associated with Coronary Heart Disease 1 is APOC3 (Apolipoprotein C3), and among its related pathways/superpathways is MicroRNAs in cancer. The drugs Atorvastatin and Olmesartan have been mentioned in the context of this disorder. Affiliated tissues include heart, endothelial and testes.

Wikipedia : 77 Coronary artery disease (CAD), also known as ischemic heart disease (IHD), involves the reduction of... more...

Description from OMIM: 607339
Sources

Related Diseases for Coronary Heart Disease 1

About this section

Diseases in the Coronary Heart Disease 1 family:

Coronary Heart Disease 3 Coronary Heart Disease 2
Coronary Heart Disease 4 Coronary Heart Disease 5
Coronary Heart Disease 7 Coronary Heart Disease 8
Coronary Heart Disease 9 Coronary Heart Disease 6

Diseases related to Coronary Heart Disease 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 594)
# Related Disease Score Top Affiliating Genes
1 diabetes mellitus, noninsulin-dependent 31.7 APOC3 CDKN2B-AS1 GAS5 MIR126 SOCS1 WFDC21P
2 lung cancer 30.6 CDKN2A CDKN2B CDKN2B-AS1 GAS5 H19 HOTTIP
3 gastric cancer 30.4 CDKN2A CDKN2B CDKN2B-AS1 GAS5 H19 HOTTIP
4 colorectal cancer 30.4 CDKN2A CDKN2B-AS1 GAS5 H19 HOTTIP MIR126
5 endometriosis 30.4 CDKN2B-AS1 H19 MIR126 MIR145
6 melanoma 30.3 CDKN2A CDKN2B-AS1 GAS5 H19 MIR182 WFDC21P
7 esophageal cancer 30.3 CDKN2A CDKN2B CDKN2B-AS1 GAS5 H19 HOTTIP
8 b-cell lymphomas 30.2 CDKN2A GAS5 MIR17
9 ovarian cancer 30.2 CDKN2B CDKN2B-AS1 GAS5 H19 MIR126 MIR145
10 prostate cancer 30.2 CDKN2B-AS1 GAS5 H19 HOTTIP IGF2-AS MIR126
11 coronary artery disease, autosomal dominant, 1 12.7
12 coronary artery disease, autosomal dominant 2 12.6
13 abdominal obesity-metabolic syndrome 3 11.9
14 coronary artery anomaly 11.7
15 sitosterolemia 11.6
16 coronary heart disease 2 11.6
17 coronary heart disease 4 11.6
18 coronary heart disease 5 11.6
19 heart disease 11.6
20 hyperlipidemia, familial combined 11.5
21 coronary heart disease 3 11.5
22 coronary heart disease 7 11.5
23 coronary heart disease 8 11.5
24 coronary heart disease 9 11.5
25 coronary heart disease 6 11.5
26 hypercholesterolemia, familial 11.5
27 angina pectoris 11.4
28 cytophagic histiocytic panniculitis 11.4
29 abdominal obesity-metabolic syndrome 1 11.4
30 cardiac arrest 11.4
31 cleft palate, cardiac defect, genital anomalies, and ectrodactyly 11.3
32 hyperlipoproteinemia, type iii 11.2
33 high density lipoprotein cholesterol level quantitative trait locus 1 11.2
34 total anomalous pulmonary venous return 1 11.2
35 hypercholesterolemia, autosomal dominant, type b 11.1
36 hyperlipidemia, combined, 2 11.1
37 hyperaldosteronism, familial, type ii 11.1
38 peripheral arterial occlusive disease 1 11.1
39 morbid obesity and spermatogenic failure 11.1
40 paget disease of bone 6 11.1
41 retinal ischemia 11.1
42 cardiovascular system disease 11.1
43 intracranial arteriosclerosis 11.1
44 retinal vascular occlusion 11.1
45 hyperlipidemia, combined, 1 11.0
46 hypoalphalipoproteinemia, primary 11.0
47 8p23.1 duplication syndrome 11.0
48 diabetes mellitus 10.8
49 depression 10.7
50 myocardial infarction 10.7

Graphical network of the top 20 diseases related to Coronary Heart Disease 1:



Diseases related to Coronary Heart Disease 1
Sources

Symptoms & Phenotypes for Coronary Heart Disease 1

About this section

Clinical features from OMIM:

607339

UMLS symptoms related to Coronary Heart Disease 1:


tremor, angina pectoris, edema, chest pain, equilibration disorder, substernal pain
Sources

Drugs & Therapeutics for Coronary Heart Disease 1

About this section

PubMedHealth treatment related to Coronary Heart Disease 1: 64

Treatments for coronary heart disease (CHD) include lifestyle changes, medicines, and medical procedures. Treatment goals may include:Relieving symptoms.Reducing risk factors in an effort to slow, stop, or reverse the buildup of plaque.Lowering the risk of blood clots forming. (Blood clots can cause a heart attack.)Widening or bypassing clogged arteries.Preventing complications of CHD.

Drugs for Coronary Heart Disease 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1144)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Atorvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 134523-00-5 60823
2
Olmesartan Approved, Investigational Phase 4,Phase 2 144689-24-7, 144689-63-4 130881 158781
3
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 68521-88-0, 11128-99-7, 4474-91-3 172198 65143
4
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 53123-88-9 46835353 6436030 5284616
5
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
6
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 159351-69-6 6442177 70789204
7
Isosorbide Dinitrate Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 87-33-2 6883
8
Metoprolol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 37350-58-6, 51384-51-1 4171
9
Trimetazidine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 5011-34-7
10
Clopidogrel Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 120202-66-6, 113665-84-2 60606
11
Aspirin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 50-78-2 2244
12
AT-101 Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 90141-22-3, 652-67-5 12597
13
Nitric Oxide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 10102-43-9 145068
14
Ticagrelor Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 274693-27-5 9871419
15
Cilostazol Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 73963-72-1 2754
16 Nutmeg Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17
Tirofiban Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 144494-65-5 60947
18
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 9005-49-6 772 46507594
19
Chlorhexidine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 55-56-1 2713 9552079
20
Simvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 79902-63-9 54454
21
Insulin glargine Approved Phase 4,Phase 3 160337-95-1
22
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7440-66-6 32051
23
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 657-24-9 14219 4091
24
Bivalirudin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 128270-60-0 16129704
25
Amlodipine Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 88150-42-9 2162
26
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 111025-46-8 4829
27
Acarbose Approved, Investigational Phase 4,Phase 3,Not Applicable 56180-94-0 441184
28
Ranolazine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 142387-99-3, 95635-55-5 56959
29
Rivaroxaban Approved Phase 4,Phase 3,Phase 2 366789-02-8
30
Warfarin Approved Phase 4,Phase 2,Phase 3,Not Applicable 81-81-2 6691 54678486
31
Cobalt Approved, Experimental Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 7440-48-4 104729
32
Chromium Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 7440-47-3 27668
33
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
34
Pitavastatin Approved Phase 4,Phase 3,Not Applicable 147526-32-7, 147511-69-1 6366718 5282452
35
Rosiglitazone Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 122320-73-4 77999
36
Lovastatin Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 75330-75-5 53232
37
Ezetimibe Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 163222-33-1 150311
38
Carvedilol Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 72956-09-3 2585
39
Tocopherol Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 1406-66-2 14986
40
Regadenoson Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 313348-27-5 219024
41
Dipyridamole Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-32-2 3108
42
Adenosine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-61-7 60961
43
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
44
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Early Phase 1,Not Applicable 113775-47-6 68602 5311068
45
Sufentanil Approved, Investigational Phase 4,Not Applicable 56030-54-7 41693
46
Ropivacaine Approved Phase 4,Not Applicable 84057-95-4 71273 175805
47
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 94-09-7, 1994-09-7 2337
48
Sevoflurane Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 28523-86-6 5206
49
tannic acid Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 1401-55-4
50
Etomidate Approved Phase 4 33125-97-2 36339 667484

Interventional clinical trials:

(show top 50) (show all 8210)
# Name Status NCT ID Phase Drugs
1 Danshen Dropping Pill for Coronary Heart Disease Heart and Artery Structure and Function Unknown status NCT01825759 Phase 4 danshen dripping pill
2 Endothelial Dysfunction in Subjects With History of Premature Coronary Artery Disease Unknown status NCT00917527 Phase 4 Atorvastatin
3 Efficacy Study of Olmesartan Medoxomil on Coronary Atherosclerosis and Epicardial Adipose Tissue(EAT) Unknown status NCT02360956 Phase 4 Olmesartan medoxomil tablets;Antihypertensive medication (per doctor suggestion)
4 Rosuvastatin Effect on Reducing Coronary Atherosclerosis Plaques Volume Unknown status NCT01382277 Phase 4 Rosuvastatin
5 Study to Investigate the Effect of Heart Rate Reduction With Ivabradine on Vascular Elastic Properties and Endothelial Function in Patients With Stable Coronary Heart Disease Unknown status NCT01768585 Phase 4 Ivabradine;Placebo
6 The Beneficial Role of Percutaneous Coronary Intervention Over Optimal Medical Therapy in Elderly Patients With Coronary Artery Disease Unknown status NCT01508663 Phase 4 ARB, CCB, ACE-inhibitor, statin, Nitrate, Antiplate etc.
7 Curative Effect Evaluation of Danlou Tablet on Coronary Artery Disease Not Amenable to Revascularization Unknown status NCT03072082 Phase 4 Danlou Tablet;DanLou Tablet placebo;Aspirin Enteric-coated Tablets;Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet;Atorvastatin calcium;Isosorbide Mononitrate Tab 20 MG;Metoprolol Tartrate Tab 25 MG;Trimetazidine Dihydrochloride Tablets
8 Curative Effect Evaluation of Shexiang Baoxin Pill on Coronary Artery Disease Not Amenable to Revascularization Unknown status NCT03072121 Phase 4 Shexiang Baoxin pill;SBP placebo;Aspirin Enteric-coated Tablets;Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet;Atorvastatin Calcium;Isosorbide Mononitrate Tab 20 MG;Metoprolol Tartrate Tab 25 MG;Trimetazidine Dihydrochloride Tablets
9 Safety and Efficacy of Low-dose Ticagrelor in Chinese Patients With Stable Coronary Artery Disease Unknown status NCT02514642 Phase 4 low-dose ticagrelor;Clopidogrel
10 The Effect of Tongguan Capsule for MicroRNA Profiles in Coronary Heart Disease Patients Unknown status NCT02850627 Phase 4 Tongguan capsule;placebo capsule
11 A Trial to Evaluate Efficacy of Heart-protecting Musk Pill Unknown status NCT01897805 Phase 4 Heart-protecting Musk Pill;Placebo
12 Effect of Cilostazol on Endothelial Progenitor Cells and Endothelial Function in Coronary Artery Disease Unknown status NCT02174939 Phase 4 Cilostazol;Dummy Placebo
13 The Prediction of Extent and Risk Profile of Coronary Atherosclerosis and Their Changes During Lipid-lowering Therapy Based on Non-invasive Techniques Unknown status NCT01773512 Phase 4 Rosuvastatin
14 The Association Between Very Small Embryonic-like Stem Cells and the Prognosis of Coronary Artery Disease Patients Unknown status NCT01633359 Phase 4 Intensive statin;Routine statin
15 Efficacy and Safety of Different Dose of Tirofiban in Interventional Treatment of Complex Coronary Artery Disease Unknown status NCT02294994 Phase 4 tirofiban
16 Firebird 2 Versus Excel Sirolimus-eluting Stent in Treating Real-world Patients With Coronary Artery Disease Unknown status NCT01373632 Phase 4
17 Pharmacodynamic Comparison of Rosuvastatin Versus Atorvastatin on Platelet Reactivity in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy With New P2Y12 Inhibitors (Trial gRANADa) Unknown status NCT02030054 Phase 4 Atorvastatin;Rosuvastatin
18 Clinical Study of Combination Therapy for Angina of Coronary Heart Disease With Aspirin and Salvianolate Injection Unknown status NCT02694848 Phase 4 Salvianolate injection;Aspirin
19 Low-dose Statins and Nutraceuticals in High-intensity Statin-intolerant Patients Unknown status NCT02001883 Phase 4 Association low-dose statin and nutraceuticals
20 Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - SAfety & EffectiveneSS of Drug-ElUting Stents & Anti-platelet REgimen Unknown status NCT01267734 Phase 4 Triple anti-platelet therapy (TAT);Double-dose clopidogrel anti-platelet therapy (DDAT)
21 The ImPact of Trimetazidine on MicrOcirculation After Stenting for Stable Coronary Artery Disease Unknown status NCT02107144 Phase 4 trimetazidine
22 Can Insulin Glargine Improve Myocardial Function in Patients With T2D and Coronary Artery Disease (CAD) Unknown status NCT01035528 Phase 4 insulin glargine;metformin
23 Comparison of TIcagrelor and Clopidogrel in Patients With Coronary Artery diseaSe and Type 2 Diabetes Mellitus (TICS-DM) Unknown status NCT02457130 Phase 4 Ticagrelor;Clopidogrel
24 Bivalirudin in Stable Ischemic Heart Disease Patients Undergoing PCI Unknown status NCT02787317 Phase 4 bivalirudin;Heparin
25 Cerebral Artery Stenosis, Coronary Artery Disease and Arrhythmia Unknown status NCT00247533 Phase 4
26 Xience/Promus for Long Coronary Lesion Registry Unknown status NCT01147237 Phase 4
27 Comparison of Biomatrix and Orsiro Drug Eluting Stent Unknown status NCT02299011 Phase 4 Biomatrix drug eluting stent
28 A Prospective Multicenter Trial Evaluating Helios Biodegradable Polymer SES Safety and Effectiveness in CAD Treatment Unknown status NCT01880879 Phase 4
29 Pharmacodynamic Effects of Atorvastatin vs. Rosuvastatin on Platelet Reactivity Unknown status NCT01567774 Phase 4 Atorvastatin;Rosuvastatin
30 Treatment of Coronary Atherosclerosis by Insulin Sensitizers in Insulin-Resistant Patients Unknown status NCT00155350 Phase 4 pioglitazone
31 Impact of Acarbose on Abnormal Glucose Regulation in Patients With Coronary Artery Disease (AAA Trial) Unknown status NCT00858676 Phase 4 acarbose
32 Fluvastatin AmelIorates aTHerosclerosis Study Unknown status NCT01681199 Phase 4 Fluvastatin extended release tablet
33 Pharmacodynamic Effects of Ranolazine Versus Amlodipine on Platelet Reactivity Unknown status NCT01490255 Phase 4 Ranolazine;Amlodipine
34 Ranolazine for Improving Symptoms of Palpitations Unknown status NCT01495520 Phase 4 Ranolazine;Placebo
35 Rivaroxaban in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention Unknown status NCT02334254 Phase 4 rivaroxaban and ticagrel therapy;triple antithrombotic regimen with warfarin, asipirin and clopidogrel
36 Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease Study Unknown status NCT02642419 Phase 4 Rivaroxaban and single antiplatelet drug (aspirin, clopidogrel or prasugrel);Rivaroxaban
37 Safety and Effectiveness of the Coronary Momo Stent Unknown status NCT01535625 Phase 4
38 Study Effects of Ginkgo Biloba Extract on Endothelial Cell Function and Genetic Effects on the Response to Ginkgo Biloba Extract in Diabetic Patients With Stable Coronary Artery Disease Unknown status NCT01038050 Phase 4 Ginkgo Biloba Extract (GBE)
39 Ranolazine, Ethnicity and the Metabolic Syndrome Unknown status NCT01304095 Phase 4 Ranolazine
40 Assessment of Surface Coverage of Two Types of DES in Diabetes Mellitus and Non- Diabetes Mellitus Unknown status NCT01023919 Phase 4
41 Overcoming High On-Treatment Platelet Reactivity (HPR) During Prasugrel Therapy With Ticagrelor Unknown status NCT01869309 Phase 4 Prasugrel;Ticagrelor
42 Comparison of Diabetes Mellitus and Non-diabetes Mellitus Patients for DES Surface COVERage by OCT Unknown status NCT01021930 Phase 4
43 PharmacOdynamic compaRison of piTavastatin Versus atOrvastatin on Platelet Reactivity Unknown status NCT01648829 Phase 4 Atorvastatin;Pitavastatin
44 Rosiglitazone Therapy In The Prevention Of Coronary Artery Disease In Patients With Impaired Glucose Tolerance Unknown status NCT00733174 Phase 4 Rosiglitazone;Placebo
45 Multivessel Stenting Versus Staged Revascularization With Zotarolimus-eluting Stent for STEMI Unknown status NCT01781715 Phase 4
46 Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis- EXtended Antiplatelet Monotherapy (HOST-EXAM) Unknown status NCT02044250 Phase 4 Clopidogrel;Aspirin
47 Cholesterol-lowering Effects of nutraceuticaLs Versus Ezetimibe in Statin-intolerant Patients Unknown status NCT01807078 Phase 4 Ezetimibe
48 Ischemia In Hemodialysed Patients: Ivabradine Versus Carvedilol Unknown status NCT01425164 Phase 4 Ivabradine;Carvedilol
49 Prospective Multicenter Registry of Hybrid Coronary Artery Revascularization Combined With Surgical Bypass and Percutaneous Coronary Intervention Using Everolimus Eluting Metallic Stents Unknown status NCT02894255 Phase 4
50 Comparison of Biolimus-eluting Biodegradable Polymer, Everolimus-eluting and Sirolimus-eluting Coronary Stents Unknown status NCT01268371 Phase 4

Search NIH Clinical Center for Coronary Heart Disease 1

Inferred drug relations via UMLS 74 / NDF-RT 52 :
Sources

Genetic Tests for Coronary Heart Disease 1

About this section

Genetic tests related to Coronary Heart Disease 1:

# Genetic test Affiliating Genes
1 Coronary Heart Disease 1 30 CX3CR1
2 Coronary Heart Disease 30
Sources

Anatomical Context for Coronary Heart Disease 1

About this section

MalaCards organs/tissues related to Coronary Heart Disease 1:

42
Heart, Endothelial, Testes, Bone, Kidney, Bone Marrow, Breast
Sources

Publications for Coronary Heart Disease 1

About this section

Articles related to Coronary Heart Disease 1:

(show top 50) (show all 4668)
# Title Authors Year
1
Psychological traits, heart rate variability, and risk of coronary heart disease in healthy aging women - the Women's Health Initiative. ( 30688770 )
2019
2
Multi-state models of transitions in depression and anxiety symptom severity and cardiovascular events in patients with coronary heart disease. ( 30845176 )
2019
3
Associations of calcium and dairy product intakes with all-cause, all-cancer, colorectal cancer, and coronary heart disease mortality among older women in the Iowa Women's Health Study. ( 30834851 )
2019
4
Shared mechanisms between coronary heart disease and depression: findings from a large UK general population-based cohort. ( 30886334 )
2019
5
Clarifying the Concept of Depression in Women With Coronary Heart Disease. ( 30864985 )
2019
6
Effect of text messaging on depression in patients with coronary heart disease: a substudy analysis from the TEXT ME randomised controlled trial. ( 30787075 )
2019
7
Depression and coronary heart disease: 2018 ESC position paper of the working group of coronary pathophysiology and microcirculation developed under the auspices of the ESC Committee for Practice Guidelines. ( 30698764 )
2019
8
Higher rates of depression among women living with Coronary Heart Disease are associated with poorer treatment outcomes and prognosis. ( 30661009 )
2019
9
Effect of rosuvastatin on vascular endothelial functions and inflammatory factors of patients with type 2 diabetes mellitus and coronary heart disease. ( 30651799 )
2019
10
Lower clearance of sodium tanshinone IIA sulfonate in coronary heart disease patients and the effect of total bilirubin: a population pharmacokinetics analysis. ( 30910058 )
2019
11
A Review of Danshen Combined with Clopidogrel in the Treatment of Coronary Heart Disease. ( 30911318 )
2019
12
Explaining the decline in coronary heart disease mortality rates in Japan: Contributions of changes in risk factors and evidence-based treatments between 1980 and 2012. ( 30826193 )
2019
13
Landmark studies in coronary heart disease epidemiology. The Framingham Heart Study after 70 years and the Seven Countries Study after 60 years. ( 30828782 )
2019
14
Reducing Coronary Heart Disease Risk Through Treatment of Insomnia Using Web-Based Cognitive Behavioral Therapy for Insomnia: A Methodological Approach. ( 30829067 )
2019
15
Statins for the Primary Prevention of Coronary Heart Disease. ( 30834266 )
2019
16
Age-Related Improvements in Peak Cardiorespiratory Fitness among Coronary Heart Disease Patients Following Cardiac Rehabilitation. ( 30841541 )
2019
17
Comparison of the Clinical Outcomes of Two Physiological Ischemic Training Methods in Patients with Coronary Heart Disease. ( 30847399 )
2019
18
Corrigendum to "Unexpectedly higher diazoxon hydrolysis by serum paraoxonase-1 in coronary heart disease" [Clinical Biochemistry 65 (2019) 21-23]. ( 30851875 )
2019
19
Monoamine oxidase inhibitors protect against coronary heart disease in rodent rat models: A pilot study. ( 30852472 )
2019
20
Sleep Disturbances in Patients With Coronary Heart Disease: A Systematic Review. ( 30853047 )
2019
21
Response by Simes et al to Letter Regarding Article, "D-Dimer Predicts Long-Term Cause-Specific Mortality, Cardiovascular Events, and Cancer in Patients With Stable Coronary Heart Disease". ( 30857403 )
2019
22
Author Correction: The prognostic significance of heart-type fatty acid binding protein in patients with stable coronary heart disease. ( 30862807 )
2019
23
Sustained blood pressure control and coronary heart disease, stroke, heart failure, and mortality: An observational analysis of ALLHAT. ( 30864748 )
2019
24
DNA methylation and hydroxymethylation are associated with the degree of coronary atherosclerosis in elderly patients with coronary heart disease. ( 30867120 )
2019
25
Association between CYP2C19*2/*3 Polymorphisms and Coronary Heart Disease. ( 30868490 )
2019
26
Interventions to support return to work for people with coronary heart disease. ( 30869157 )
2019
27
Coronary heart disease diagnosis by artificial neural networks including aortic pulse wave velocity index and clinical parameters. ( 30870247 )
2019
28
Comparison of secondary prevention in coronary heart disease patients living in rural and urban areas. ( 30874515 )
2019
29
Light Physical Activity and Incident Coronary Heart Disease and Cardiovascular Disease Among Older Women-A Call for Action. ( 30874773 )
2019
30
Association of Light Physical Activity Measured by Accelerometry and Incidence of Coronary Heart Disease and Cardiovascular Disease in Older Women. ( 30874775 )
2019
31
Study on correlation between property of coronary artery lesion and degree of coronary artery stenosis of elderly patients with coronary heart disease. ( 30881430 )
2019
32
An unbiased lipid phenotyping approach to study the genetic determinants of lipids and their association with coronary heart disease risk factors. ( 30887811 )
2019
33
Pulse pressure correlates with coronary artery calcification and risk for coronary heart disease: a study of elderly individuals in the rural region of Southwest China. ( 30888975 )
2019
34
Subsequent Event Risk in Individuals with Established Coronary Heart Disease: Design and Rationale of the GENIUS-CHD Consortium. ( 30896328 )
2019
35
Association of Chromosome 9p21 with Subsequent Coronary Heart Disease Events: A GENIUS-CHD Study of Individual Participant Data. ( 30897348 )
2019
36
Cardiovascular and Lifestyle Risk Factors and Cognitive Function in Patients With Stable Coronary Heart Disease. ( 30897999 )
2019
37
The Expression and Clinical Significance of Spleen Tyrosine Kinase in Patients with Coronary Heart Disease. ( 30898992 )
2019
38
Coronary Heart Disease and Dietary Carbohydrate, Glycemic Index, and Glycemic Load: Dose-Response Meta-analyses of Prospective Cohort Studies. ( 30899909 )
2019
39
Increased risk of coronary heart disease among patients with idiopathic inflammatory myositis: a nationwide population study in Taiwan. ( 30903193 )
2019
40
Computed tomography coronary angiography vs. standard diagnostic procedure for the diagnosis of angina due to coronary heart disease: A cross-sectional study. ( 30906436 )
2019
41
Decoy receptor-3 regulates inflammation and apoptosis via PI3K/AKT signaling pathway in coronary heart disease. ( 30906453 )
2019
42
A Large-Scale, Multi-Center Urine Biomarkers Identification of coronary heart disease in TCM Syndrome Differentiation. ( 30907085 )
2019
43
Circulating Hematopoietic Stem/Progenitor Cells are Associated with Coronary Stenoses in Patients with Coronary Heart Disease. ( 30737465 )
2019
44
Urinary phthalate metabolites, coronary heart disease, and atherothrombotic markers. ( 30753939 )
2019
45
Targeted metabolomic analysis of plasma metabolites in patients with coronary heart disease in southern China. ( 30762730 )
2019
46
Lifetime Risk of Stroke and Coronary Heart Disease Deaths According to Blood Pressure Level: EPOCH-JAPAN (Evidence for Cardiovascular Prevention From Observational Cohorts in Japan) ( 30763510 )
2019
47
Insulin-like growth factor-binding protein 7 (IGFBP 7) as a new biomarker in coronary heart disease. ( 30769262 )
2019
48
The pleiotropic effect of statins on the atherosclerotic plaque and coronary heart disease. ( 30770174 )
2019
49
Assessment of risk of fasting during Ramadan under optimal diabetes care, in high-risk patients with diabetes and coronary heart disease through the use of FreeStyle Libre flash continuous glucose monitor (FSL-CGMS). ( 30771364 )
2019
50
Cholesterol goal achievement and lipid-lowering therapy in patients with stable or acute coronary heart disease in Singapore: results from the Dyslipidemia International Study II. ( 30773600 )
2019